Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.

PHASE3RecruitingINTERVENTIONAL
Enrollment

426

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2030

Conditions
Resectable Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Camrelizumab

The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.

RADIATION

radiotherapy

The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.

Trial Locations (5)

200000

RECRUITING

Shanghai Chest Hospital, Shanghai

Unknown

RECRUITING

Anyang Tumour Hospital, Anyang

RECRUITING

Sun yat-sen University Cancer Center, Guangzhou

RECRUITING

Anhui Provincial Hospital, Hefei

RECRUITING

Zhongshan Hospital of Fudan University, Shanghai

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Zhigang Li

OTHER

NCT05043688 - Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. | Biotech Hunter | Biotech Hunter